| Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease D Harold, R Abraham, P Hollingworth, R Sims, A Gerrish, ML Hamshere, ... Nature genetics 41 (10), 1088-1093, 2009 | 3317 | 2009 |
| Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing BW Kunkle, B Grenier-Boley, R Sims, JC Bis, V Damotte, AC Naj, ... Nature genetics 51 (3), 414-430, 2019 | 2268 | 2019 |
| Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease P Hollingworth, D Harold, R Sims, A Gerrish, JC Lambert, ... Nature genetics 43 (5), 429-435, 2011 | 2197 | 2011 |
| New insights into the genetic etiology of Alzheimer’s disease and related dementias C Bellenguez, F Küçükali, IE Jansen, L Kleineidam, S Moreno-Grau, ... Nature genetics 54 (4), 412-436, 2022 | 1016 | 2022 |
| Susceptibility locus for Alzheimer's disease on chromosome 10 A Myers, P Holmans, H Marshall, J Kwon, D Meyer, D Ramic, S Shears, ... Science 290 (5500), 2304-2305, 2000 | 491 | 2000 |
| SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Aβ‐Degrading Enzymes in Alzheimer's Disease JS Miners, S Baig, J Palmer, LE Palmer, PG Kehoe, S Love Brain pathology 18 (2), 240-252, 2008 | 473 | 2008 |
| A full genome scan for late onset Alzheimer's disease P Kehoe, FWD Vrieze, R Crook, WS Wu, P Holmans, I Fenton, G Spurlock, ... Human Molecular Genetics 8 (2), 237-245, 1999 | 450 | 1999 |
| Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease L Jones, PA Holmans, ML Hamshere, D Harold, V Moskvina, D Ivanov, ... PloS one 5 (11), e13950, 2010 | 445 | 2010 |
| Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease PG Kehoe, C Russ, S McIlroy, H Williams, P Holmans, C Holmes, ... Nature genetics 21 (1), 71-72, 1999 | 346 | 1999 |
| Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the vascular impairment of cognition classification consensus study OA Skrobot, SE Black, C Chen, C DeCarli, T Erkinjuntti, GA Ford, ... Alzheimer's & Dementia 14 (3), 280-292, 2018 | 332 | 2018 |
| Aβ-degrading enzymes: potential for treatment of Alzheimer disease JS Miners, N Barua, PG Kehoe, S Gill, S Love Journal of Neuropathology & Experimental Neurology 70 (11), 944-959, 2011 | 318 | 2011 |
| Drug repositioning for Alzheimer's disease A Corbett, J Pickett, A Burns, J Corcoran, SB Dunnett, P Edison, JJ Hagan, ... Nature reviews Drug discovery 11 (11), 833-846, 2012 | 315 | 2012 |
| Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias NM Davies, PG Kehoe, Y Ben-Shlomo, RM Martin Journal of Alzheimer's Disease 26 (4), 699-708, 2011 | 260 | 2011 |
| Cognitive impact of COVID-19: looking beyond the short term S Miners, PG Kehoe, S Love Alzheimer's research & therapy 12 (1), 170, 2020 | 256 | 2020 |
| Large Meta-Analysis Establishes the ACE Insertion-Deletion Polymorphism as a Marker of Alzheimer's Disease DJ Lehmann, M Cortina-Borja, DR Warden, AD Smith, K Sleegers, ... American journal of epidemiology 162 (4), 305-317, 2005 | 253 | 2005 |
| Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment OA Skrobot, J Attems, M Esiri, T Hortobágyi, JW Ironside, RN Kalaria, ... Brain 139 (11), 2957-2969, 2016 | 251 | 2016 |
| Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease? PG Kehoe, GK Wilcock The Lancet Neurology 6 (4), 373-378, 2007 | 226 | 2007 |
| Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier S Krol, R Macrez, F Docagne, G Defer, S Laurent, M Rahman, ... Chemical reviews 113 (3), 1877-1903, 2013 | 214 | 2013 |
| The vascular impairment of cognition classification consensus study OA Skrobot, J O'Brien, S Black, C Chen, C DeCarli, T Erkinjuntti, GA Ford, ... Alzheimer's & Dementia 13 (6), 624-633, 2017 | 213 | 2017 |
| Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology PG Kehoe, S Wong, N Al Mulhim, LE Palmer, JS Miners Alzheimer's research & therapy 8, 1-10, 2016 | 207 | 2016 |
